Summary & Overview
CPT 0452U: EarlyTect® Bladder Cancer Detection, PENK Methylation Urine Assay
CPT code 0452U identifies a proprietary molecular diagnostic assay — EarlyTect® Bladder Cancer Detection — that measures methylated PENK DNA in urine via LTE–qMSP and reports the likelihood of bladder cancer. As a PLA code, 0452U applies uniquely to Promis Diagnostics Inc.'s test and signals an advanced, manufacturer-specific laboratory service that may affect coding, billing, and coverage reviews nationwide. The code matters because urine-based methylation assays offer a noninvasive option for bladder cancer detection and can influence diagnostic pathways and utilization of molecular diagnostics across health plans.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, payer coverage considerations, and typical service and site-of-service context. The publication summarizes national benchmarking and policy implications for a PLA-coded molecular diagnostic, highlights clinical context for PENK methylation as a bladder cancer biomarker, and notes where input data are not available. This resource is intended for coding and reimbursement professionals, laboratory managers, and clinicians seeking a clear national-level summary of CPT code 0452U and its role in bladder cancer diagnostic services.
Billing Code Overview
CPT code 0452U is a Proprietary Laboratory Analyses (PLA) code for EarlyTect® Bladder Cancer Detection (EarlyTect® BCD), manufactured by Promis Diagnostics Inc. The test analyzes a urine specimen using linear target enrichment–quantitative methylation–specific real–time PCR (LTE–qMSP) to detect methylated PENK DNA. Results are reported as the likelihood of bladder cancer based on PENK methylation, a biomarker associated with bladder cancer.
Service Type: Proprietary molecular diagnostic laboratory test (urine-based methylation assay)
Typical Site of Service: Clinical laboratory or specialized molecular diagnostics laboratory; sample collected in outpatient settings
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of tobacco use presents to urology with painless gross hematuria and intermittent urinary frequency. The urologist orders the EarlyTect® Bladder Cancer Detection test (report with CPT code 0452U) on a voided urine specimen to assess the likelihood of bladder cancer using methylated PENK DNA detected by LTE–qMSP. Specimen collection occurs in the outpatient clinic or an affiliated phlebotomy/laboratory draw site; the sample is sent to the manufacturer's designated laboratory for proprietary testing. Results are returned as a probability or likelihood of bladder cancer and are used alongside cystoscopy, urine cytology, and imaging to guide decisions such as performing diagnostic cystoscopy, biopsy, or surveillance scheduling. Typical workflow: patient presents → clinician documents indication (hematuria, surveillance of prior urothelial carcinoma, or suspicious urine cytology) → voided urine specimen collected and labeled → specimen shipped per manufacturer instructions to the performing lab → laboratory performs LTE–qMSP for PENK methylation → report issued to ordering clinician, who documents interpretation and next-step plan in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier used / default | Use when no additional modifier applies to the service |